India ka opioid landscape complex hai. Ek side: India globally under-treats pain — pharmacy level opioid-phobia, regulatory bottlenecks (NDPS Act), cancer patients ko bhi adequate pain relief nahi milti. Lancet Commission on Global Access to Pain Relief ne India ko specifically flag kiya hai.
Doosri side: long-term opioid use for chronic non-cancer pain globally controversial hai. US opioid crisis ke baad evidence base shift hua hai — chronic non-cancer pain me opioids first-line nahi hain. Functional improvement limited, addiction + tolerance + dependence risk real.
India-specific issues:
- Tramadol over-prescription: Tramadol weak opioid + SNRI hybrid hai. India me commonly mis-prescribed — GP level pe routine pain medication banayi gayi hai. Dependence + serotonin syndrome risk real hai (especially SSRIs ke saath).
- OTC codeine cough syrups: Misuse epidemic Northeast + Punjab me documented. Pain self-medication ke through addiction shuru hoti hai.
- Lack of pain clinics: ISSP-certified pain specialists tier-2/3 cities me almost zero. Patients GP ya orthopedic pe stuck rehte hain.
- Stigma both ways: Cancer patient ko morphine na milna AND chronic back pain patient ko tramadol month after month — dono problems coexist karte hain.
Bottom line: Opioids ka decision pain specialist ke saath collaborative hona chahiye. Risk-benefit assessment, written agreement, regular review, urine drug screening jab indicated, taper plan ready. Never self-medicate, never internet pharmacy.